130 related articles for article (PubMed ID: 9241083)
1. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group.
Carpenter PA; White L; McCowage GB; Nayanar V; Toogood I; Shaw PJ; Lockwood L; Tiedemann K
Cancer; 1997 Aug; 80(3):489-96. PubMed ID: 9241083
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
McCowage GB; White L; Carpenter P; Lockwood L; Toogood I; Tiedemann K; Shaw PJ
Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
[TBL] [Abstract][Full Text] [Related]
3. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.
White L; McCowage G; Kannourakis G; Nayanar V; Colnan L; Kellie S; Shaw P; Seshadri R; Lockwood L; Tiedemann K
J Clin Oncol; 1994 Mar; 12(3):522-31. PubMed ID: 8120550
[TBL] [Abstract][Full Text] [Related]
4. Treatment of children with poor risk solid tumors by further escalation of the VETOPEC regimen including very high-dose cyclophosphamide and peripheral stem cell support: an Australian and New Zealand Children's Hematology and Oncology Group study.
McCowage GB; Mrongovius R; Alvaro F; Cohn RJ; Ziegler DS; Oswald C; White L;
Pediatr Blood Cancer; 2011 Dec; 57(6):958-64. PubMed ID: 21793175
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of vincristine and etoposide with escalating cyclophosphamide in poor-prognosis pediatric brain tumors.
Ziegler DS; Cohn RJ; McCowage G; Alvaro F; Oswald C; Mrongovius R; White L;
Neuro Oncol; 2006 Jan; 8(1):53-9. PubMed ID: 16443948
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of sequential high-dose chemotherapy and peripheral blood stem cell support for pediatric central nervous system malignancies.
Jakacki RI; Jamison C; Heifetz SA; Caldemeyer K; Hanna M; Sender L
Med Pediatr Oncol; 1997 Dec; 29(6):553-9. PubMed ID: 9324343
[TBL] [Abstract][Full Text] [Related]
7. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children's Cancer Study Group (ANZCCSG).
White L; Kellie S; Gray E; Toogood I; Waters K; Lockwood L; Macfarlane S; Johnston H
J Pediatr Hematol Oncol; 1998; 20(2):125-30. PubMed ID: 9544162
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
9. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
Yeung AW; Pang YK; Tsang YC; Wong SW
Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
[TBL] [Abstract][Full Text] [Related]
10. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors.
Kreissman SG; Rackoff W; Lee M; Breitfeld PP
J Pediatr Hematol Oncol; 1997; 19(4):309-12. PubMed ID: 9256829
[TBL] [Abstract][Full Text] [Related]
11. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
12. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
Ozkaynak MF; Matthay K; Cairo M; Harris RE; Feig S; Reynolds CP; Buckley J; Villablanca JG; Seeger RC
J Clin Oncol; 1998 Mar; 16(3):937-44. PubMed ID: 9508176
[TBL] [Abstract][Full Text] [Related]
13. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
[TBL] [Abstract][Full Text] [Related]
14. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
17. High-dose cyclophosphamide, adriamycin, and vincristine (HD-CAV) in children with recurrent solid tumor.
Zoubek A; Holzinger B; Mann G; Peters C; Emminger W; Perneczky-Hintringer E; Gadner H; Mostbeck G; Horcher E; Dobrowsky W
Pediatr Hematol Oncol; 1994; 11(6):613-23. PubMed ID: 7857784
[TBL] [Abstract][Full Text] [Related]
18. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
